1. Home
  2. LQDA vs WLKP Comparison

LQDA vs WLKP Comparison

Compare LQDA & WLKP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LQDA

Liquidia Corporation

HOLD

Current Price

$33.37

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo Westlake Chemical Partners LP Common Units representing limited partner interests

WLKP

Westlake Chemical Partners LP Common Units representing limited partner interests

HOLD

Current Price

$19.83

Market Cap

652.0M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
LQDA
WLKP
Founded
2004
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
652.0M
IPO Year
2018
2014

Fundamental Metrics

Financial Performance
Metric
LQDA
WLKP
Price
$33.37
$19.83
Analyst Decision
Strong Buy
Analyst Count
10
0
Target Price
$37.40
N/A
AVG Volume (30 Days)
1.7M
65.1K
Earning Date
11-03-2025
10-30-2025
Dividend Yield
N/A
9.56%
EPS Growth
N/A
N/A
EPS
N/A
1.39
Revenue
$69,216,000.00
$1,133,706,000.00
Revenue This Year
$904.79
$3.88
Revenue Next Year
$188.25
$12.71
P/E Ratio
N/A
$14.14
Revenue Growth
343.41
N/A
52 Week Low
$10.37
$17.75
52 Week High
$35.54
$25.04

Technical Indicators

Market Signals
Indicator
LQDA
WLKP
Relative Strength Index (RSI) 61.68 65.10
Support Level $32.11 $18.88
Resistance Level $35.54 $19.19
Average True Range (ATR) 1.60 0.37
MACD -0.12 0.18
Stochastic Oscillator 70.82 91.14

Price Performance

Historical Comparison
LQDA
WLKP

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About WLKP Westlake Chemical Partners LP Common Units representing limited partner interests

Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.

Share on Social Networks: